a b s t r a c t T cell-dependent IgM antibody production and natural killer cell (NKC) activity were assessed in SD rats orally administered atrazine for 28 days to males (0, 6.5, 25, or 100 mg/kg/day) or females (0, 3, 6, or 50 mg/kg/day), or 30 or 500 ppm in diet (3 or 51 mg/kg/day). Anti-asialo GM1 antibodies (NKC) and cyclophosphamide (antibody-forming cell assay [AFC]) served as positive controls. Pituitary (ACTH, prolactin), adrenal (corticosterone, progesterone, aldosterone), and gonadal (androgens, estrogens) hormones were assessed after 1, 7, and/or 28 days of treatment. Food intake and body weights were significantly reduced in the highest dosed males, and transiently affected in females. Urinary corticosterone levels were not increased in atrazine-treated groups in either sex at any time point measured (10, 22, or 24 days). Corticosterone and progesterone were elevated in males after a single atrazine dose !6.5 mg/kg/day, but not after 7, 14, or 28 doses. There were no effects on adrenal, pituitary, or gonadal hormones in females. Atrazine did not suppress the AFC response or decrease NKC function after 28 days in males or females. Atrazine had no effect on spleen weights or spleen cell numbers in males or females, although thymus weights were elevated in males receiving the highest dose. The lack of immunotoxic effect of atrazine was associated with diminished adrenal activation over time in males, and no effects on adrenal hormones in females.
Introduction

Atrazine
[(2-chloro-4-(ethylamino)-6-(isopropylamino)-striazine)] is a chlorotriazine herbicide that is used to control annual grasses and some broadleaf weeds (Gianessi and Marcelli, 2000) . The herbicidal action of triazines is based upon inhibition of photosynthesis by blocking electron transfer at the reducing site of chloroplast complex II. Although the toxicity of atrazine has been well characterized (Breckenridge et al., 2008; Simpkins et al., 2011) , there have been relatively few systematic investigations of its immunotoxic potential. The results from in vitro studies suggest that atrazine may adversely affect cytokine production (Devos et al., 2003; Hooghe et al., 2000) ; the mitogenic activation and survival of lymphocytes (Chen et al., 2015; Lee et al., 2016; Pistl et al., 2003) ; mast cell degranulation (Mizota and Ueda, 2006) ; macrophage function (Karrow et al., 2005) ; the cytolytic activity of NKC (Rowe et al., 2007; Whalen et al., 2003) ; and the functional integrity of dendritic-like cells (Pinchuk et al., 2007; Thueson et al., 2015) . However, there are only a limited number of studies on the effect of atrazine on immune function in vivo (Fournier et al., 1992; Karrow et al., 2005) . Studies have also been conducted on the immunotoxicity potential of atrazine during development (Filipov et al., 2005; Rooney et al., 2003; Rowe et al., 2006 Rowe et al., , 2008 , but as noted by the USEPA (EPA, 2010) , the results from these investigations have been inconsistent. Acute doses of atrazine, when administered by gavage to male (Laws et al., 2009; Pruett et al., 2008) or female rats (Fraites et al., 2009) or female mice (Pruett et al., 2003 (Pruett et al., , 2009 ) activate the hypothalamic-pituitary-adrenal (HPA) axis, as indicated by elevated plasma concentrations of ACTH and/or corticosterone. The adrenal response to acute stressors has been used to predict changes in immunological parameters (Pruett, 2001; Pruett et al., 1999 Pruett et al., , 2000 Pruett et al., , 2003 Pruett et al., 2003) . Measurement of immunological parameters in relation to adrenal activation in atrazinetreated animals has only been reported once previously and was performed in female mice administered 150 mg/kg of atrazine intraperitoneally (Pruett et al., 2009) . Thus, the current study was conducted to evaluate the adrenal response following repeated doses of atrazine administered orally over time and to determine if atrazine induces immunotoxicity using standard 28-day exposure protocols developed to assess such effects (USEPA, 1998) .
In order to assess the effects of atrazine exposure on the HPA axis and immune function, young adult male and female Sprague Dawley rats were administered atrazine for up to 28 days (males: at 6.5, 25, or 100 mg/kg via gavage; females: at 3, 6, or 50 mg/kg/day via gavage, or at 30 or 500 ppm in the diet). Furthermore, considering the rapid phase 1 metabolism and pharmacokinetic clearance of atrazine and its mono-dealkylated metabolites (de-ethyl atrazine [DEA] and de-isopropyl atrazine [DIA] ) from plasma following bolus dose administration (Campbell et al., 2016) , additional groups of female rats that were administered atrazine in diet for 28 days were included in the study. This permitted an assessment of the impact of pharmacokinetics on immunotoxicity parameters and urinary corticosterone levels after 4 weeks of dosing in the diet compared with animals that were administered equivalent doses by gavage. The results indicated that the HPA axis was activated after a single dose of atrazine in males, however, the adrenal response habituated over time and was not evident by day 7 of treatment. No effects of treatment were noted on the integrity of splenic antibody production (AFC assay) or NKC activity after 28 days of treatment.
Materials and methods
Animals
The protocols used for the in-life phase of these studies were approved by the Animal Care and Use Committee of WIL Research, Ashland, OH. Animals were maintained in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011) and with NIH and AAALAC guidelines. Rats were used as the test system on this study. This animal model is recognized as appropriate for toxicity studies with atrazine. Rooney et al. (2003) reported that the rat is responsive to the effects of atrazine on immune system parameters (Rooney et al., 2003) . In addition, the use of rats removed the need to pool samples to perform hematology tests and hormone assays in individual animals in each treatment group. In addition, the majority of previous studies describing atrazine activation of the HPA have been performed in the rat.
Young adult females were approximately 8e9 weeks of age upon receipt and a minimum of 12.5 weeks at initiation of treatment. Males were 10 weeks of age at arrival and 11 weeks of age at initiation of treatment. All male and female Sprague-Dawley rats [Crl:CD (SD)] were purchased from Charles River Laboratories (Raleigh, NC) and were housed individually in suspended wiremesh cages under controlled temperature (22 ± 3 C) and humidity (50± 20%). Females were maintained on a 14-hr light (0500 he1900 h)/10-hr dark photoperiod, whereas males were maintained on a 12-hr light (0600 he1800 h)/12-hr dark cycle. All animals had ad libitum access to food (LabDiet ® 5002, PMI Nutritional, LLC) and water (reverse osmosis-purified) throughout the duration of the acclimation period and study. Males in the pair-fed (PF) control group were given the average amount of feed consumed on the prior day by animals administered the highest dose of atrazine (100 mg/kg/day). All animals were deprived of food during the urine collection phase of the study. Male studies were confined to the assessment of adrenal hormones and immune function. Female treatments were performed in conjunction with other female animals designed to determine the effects of repeated atrazine treatments on estrous cyclicity, luteinizing hormone (LH) surge, and metrics of fertility. In females, atrazine was delivered in bolus doses via gavage or distributed doses via atrazine incorporated in animal chow. The results of repeated atrazine treatment on female rat fecundity can be found in a previous publication (Foradori et al., 2014) ; the immunosuppressive effects of atrazine on females were consolidated with male studies in the present report. Immunotoxicity studies commonly use 28 days of treatment to assess possible effects. In the current studies, tissues from separate male treatment groups were examined for atrazine's proposed effects on adrenal and gonadal hormones on 1, 7, 14, or 28 days of treatment. After it was determined that atrazine had little or no effect on adrenal and gonadal hormones levels after 1e7 days of treatment, female animals were treated for 28 days to determine immunotoxic effects. 
Test and control materials
Test article homogeneity, stability, and formulation concentration
It was determined that atrazine was homogeneously distributed in the 1% methylcellulose suspensions and in powdered Rodent LabDiet prior to the commencement of dosing. Aqueous and feed samples were determined to be stable for 11e15 days when stored at either room temperature or À20 C. The concentration of atrazine in each dose formulation was assessed by HPLC and was found to be within acceptable limits of target concentrations in the study in males (Supplemental Table 1 ) and females (Supplemental Table 2 ). Atrazine was not detected in any vehicle control samples. These analyses assured that the intended dose of atrazine was administered.
Amendment of 1988 (Congress, 1988) .
Treatments for immunological assessments (NKC and AFC assays)
NKC and AFC assays were conducted in rats treated with atrazine (males: gavage; females: gavage and dietary) for 28 days prior to tissues collection. The specific atrazine treatment regimens and assessment parameters for the male and female rats are described in separate sections below.
Males and females in the positive control group for the NKC assay were administered 1.0 mL of a 1:10 dilution of AA by intravenous injection (i.v.) , approximately 24 h prior to tissue collection. Males and females assigned to the AFC assay were immunized with an intravenous injection of red blood cells (0.5 mL of Earle's Balanced Salt Solution (EBSS) with HEPES containing 2.0 Â 10 8 sheep red blood cells [SRBC] ) approximately 96 h prior to euthanasia. Animals in the splenic AFC assay positive control group were administered CPS (50 mg/kg/day) by intraperitoneal injection once daily for 4 consecutive days prior to tissue collection. The first dose of CPS was given after immunization with SRBC.
Study design in male rats (oral gavage)
Atrazine (6.5, 25 or 100 mg/kg/day; dose volume ¼ 5 mL/kg) was administered by oral gavage daily for 1, 7, 14, or 28 days at approximately 0900 h. A concurrent vehicle control group received 1% methylcellulose in deionized water. An additional PF control group was administered the vehicle and, beginning on study day 1, was fed the average amount of feed consumed on the previous day by animals in the 100 mg/kg/day atrazine group. Separate cohorts of male rats were used to evaluate the plasma concentrations of adrenal, pituitary, and gonadal hormones in samples collected approximately 30 min following dosing on day 1, 7, 14, or 28 (Table 1 ). The NKC assay was conducted in the same cohort of male rats used to evaluate plasma hormone concentrations, whereas the AFC assay was conducted in a separate cohort of male rats after 28 days of atrazine treatment. Each group was comprised of a minimum of 10 rats.
Body weights (BW) and food consumption were recorded daily for all males (Supplemental Tables 3). Urine was collected from all males in metabolic cages for approximately 6 h for vehicle control, atrazine, and PF groups on study days 10 and 24. During the 6-h urine collection period, males were food-fasted, although water was available ad libitum. At the end of the collection period, urine was transferred into individually-labeled tubes. Individual sample volumes were measured and samples were stored frozen at À70 C.
Study design in female rats (oral gavage and dietary)
Vaginal lavages were performed daily for 14 days to determine the stage of estrus, prior to females being randomly assigned to treatment groups. Only females with regular 4-day estrous cycles during the pre-treatment period were used in the study. These data, which were part of a sub-study on the effect of atrazine on the luteinizing hormone (LH) surge, have been published elsewhere (Foradori et al., 2014) . Since all animals received their first dose on the day of estrus, the estrous cycle was effectively synchronized with respect to dose day for as long as the animals maintained a 4-day cycle. Initiation of dosing in conjunction with the estrous cycle allowed for determination of the effects of atrazine on the estrous cycle (Supplemental Table 6 ) and allowed for control of estrouscycle-dependent physiology, specifically gonadal hormones and immune function (Baral et al., 1995; Page and Ben-Eliyahu, 1997; Prabhala and Wira, 1995) .
Female rats, which were randomly assigned to groups (Table 2) , were administered atrazine for a minimum of 28 consecutive days either via the diet (0, 30, and 500 ppm), or by oral gavage (0, 3, 6, or 50 mg/kg/day). The NKC and AFC assays were conducted in separate cohorts of female rats. Blood for plasma hormone concentration analysis was collected in the same cohort of female rats used for the NKC assay. For the females treated by gavage, blood was collected approximately 30 min after treatment. Each group was comprised of a minimum of 10 rats. During the dosing period, control rats for dietary exposure were fed untreated basal diet, and control animals for oral gavage exposure received vehicle alone.
Body weights and food consumption were recorded daily. Approximately 6 days prior to termination, females were placed in metabolic cages to collect urine. Urine collection was initiated immediately following dose administration and the animals remained in metabolic cages without food or water for an approximate 6-h collection period. This was followed by a 3-h period where the animals had ad libitum access to feed and water in their home cage. Following the 3-h interim period, animals were subjected to a second 6-h urine collection period in a clean metabolic cage, followed by a second 3-h interim period, and then a third 6-h collection period. The third 6-h collection period ended just prior to dose administration the following day. To reduce variability, all animals were in diestrus of the ovarian cycle when placed in metabolic cages. Individual urine sample volume was measured and all samples were stored frozen at À70 C.
Blood collection (males and females)
In order to minimize stress on the animals, noise in the animal room and handling of the animals prior to euthanasia (and during blood collection) were kept to an absolute minimum. Each animal was removed from its home cage and euthanized as swiftly as possible in an ante-room. All animals were euthanized by decapitation approximately 30 min following the final gavage dose (males and females). Dietary animals (females) were euthanized at the same time as the gavaged animals.
Blood samples were collected immediately after decapitation, placed in wet ice, and protected from light until centrifugation. All samples were centrifuged (2000 Â g for 10 min) at 4 C. Plasma aliquots were collected into uniquely-labeled polypropylene tubes for separate analysis of corticosterone, progesterone, estradiol, estrone, estriol, prolactin, androstenedione, and testosterone. Tubes containing plasma for adrenocorticotropic hormone and prolactin assays were pre-filled with aprotinin (0.4 Trypsin Inhibitor Unit).
Evaluation of immunological endpoints (males and females)
Terminal whole body, spleen, and thymus weights were measured. The ability of rats to mount IgM anti-SRBC antibody responses was evaluated by determining the number of AFC in the spleen. NKC function of splenocytes was measured using a standard cytotoxicity assay described below:
Preparation of splenocytes
Single cell suspensions of splenocytes were prepared using a Stomacher ® Blender. Cell suspensions were then centrifuged (1200 rpm for 10 min @ 4 C) and suspended in EBSS buffered with HEPES. Cell viability was determined by analytical flow cytometry (Coulter Epics XL-MCL) using propidium iodide staining.
Antibody forming cell (AFC) assay
The primary IgM antibody response to SRBC was measured using a modified hemolytic plaque assay (Jerne and Nordin, 1963) . Splenocyte suspensions were diluted (1:50 and 1:150) and a 0.1 mL aliquot from each suspension was added to separate test tubes, each containing 25 ml of guinea pig complement, 25 ml of SRBC, and 0.5 mL of warm agar (0.5%). After thorough mixing, the contents of each test were plated onto a separate petri dish, covered with a microscope cover slip, and incubated at 37 C for 3 h. Two AFC parameters were measured: Specific Activity (AFC/10 6 spleen cells)
and Total Spleen Activity (AFC/spleen). AFC plaques were counted using a Bellco plaque viewer.
2.9.3. Natural killer cell (NKC) assay NKC function was evaluated using a modification of the method described by Djeu (1995) . YAC-1 target cells (ATCC, Manassas, VA) were radiolabeled using sodium chromate (Na 51 CrO 4 ), washed and adjusted to a concentration of 5 Â 10 4 viable cells per ml. Labeled YAC-1 cells were added to wells of a 96-well plate in a 100 ml volume. Spleen cell (effector cell) preparations were then added in 100 ml aliquots to provide effector:target (E:T) ratios ranging from 200:1 to 6.25:1. Plates were cultured at 37 C for 4 h and the extent of target cell lysis was determined by measuring the amount of isotope released into the supernatant. Results were expressed as net percent cytotoxicity.
2.9.4. Hormone assays (males and females) 2.9.4.1. Radioimmunoassay for corticosterone. Corticosterone was assayed using radioimmunoassay. Plasma samples were diluted in 0.01 M PBS (1:25) and corticosteroid-binding globulin was inactivated by incubation at 65 C for 1 h. Samples and standards (5e700 ng/mL) were incubated overnight at 4 C with antiserum (rabbit anti-corticosterone; MP Biomedicals, Solon, OH, USA) and [3H] corticosterone (PerkinElmer, Boston, MA, USA) in 0.1% gelatin in 0.01 PBS. Free corticosterone was separated from antibodybound corticosterone by the addition of 1.0 mL dextran-coated charcoal followed by centrifugation (2000 Â g for 15 min). After centrifugation, the supernatant, containing antibody-bound corticosterone was mixed with 4 mL of scintillation fluid and counted with a Beckman Coulter LS 6500 liquid scintillation counter (Brea, CA, USA). Mean intra-and inter-assay coefficients of variation were 7.9 and 9.0%, respectively (2 assays). To determine urinary corticosterone concentration, the same procedure was performed without dilution of primary sample and without heat denaturation. The mean intra-assay coefficient of variation was 7.3% for plasma samples and 6.2% for urine.
2.9.4.2. ELISAs for progesterone, ACTH, and prolactin. Progesterone, ACTH, and prolactin were assayed using commercially available kits and following supplier provided protocols (Progesterone EIA KIT, Cayman Chemical, 418258; Rat ACTH Ultrasensitive lumELISA, CalBiotech, ACT3186; Prolactin (rat) EIA Kit, Cayman Chemical, 0419296-1). All quality controls (QC) and calibration standards met acceptability criteria, as they were within 2 standard deviations of historical averages. Sample values that fell outside the acceptable range of the standard curve (20e80%) were diluted appropriately and re-assayed until they were within range.
2.9.4.3. LC-MS/MS analyses for aldosterone, androstenedione, estrone, estradiol, estriol, progesterone, testosterone, and dihydrotestosterone. Frozen serum samples were shipped to NMS labs (Willow Grove, PA) for analysis of aldosterone, androstenedione, estrone, estradiol, estriol, progesterone, testosterone, and dihydrotestosterone (DHT) using liquid chromatography/tandem mass spectrometry (LC-MS/MS). The quantification of plasma steroid levels was evaluated using three separate testing panels.
Estrone, estradiol, estriol, and aldosterone were quantitated using one testing procedure. After thawing, isotopically-labeled internal standards for all four analytes were added to 200 mL aliquots of samples, and they were diluted with acetonitrile to precipitate proteins. Samples were analyzed by HPLC and LC-MS/MS with electrospray ionization in the negative mode. One ion transition was monitored for each analyte and internal standard. Six levels of calibration were run for all four analytes, but only estrone and estradiol used all concentrations of 2, 5, 10, 50, 100, and 500 pg/ mL. Four levels of calibration were used for estriol and aldosterone at 10, 50, 100, and 500 pg/mL. Three levels of quality control samples were dispersed throughout the analytical batch at concentrations of 20, 100, and 200 pg/mL for each of the four analytes in this panel. Androstenedione, progesterone, corticosterone, and testosterone were detected and quantitated using a second procedure. After thawing, isotopically-labeled internal standards in acetonitrile for all four analytes were added to 100 mL aliquots of samples.
Following centrifugation, samples were diluted with water and analysis was by LC-MS/MS with atmospheric pressure photoionization in the positive mode. Toluene was used as the doping agent in the ionization chamber. One ion transition was monitored for each analyte and the internal standard. Five levels of calibration were run for androstenedione at 5, 25, 100, 250, and 500 ng/dL. Five calibration standards were run for corticosterone (10, 50, 200, 500 , and 1000 ng/dL), seven for progesterone (3, 10, 15, 75, 300, 750 , and 1500 ng/dL) and six for testosterone at (2.2, 12, 55, 220, 550, and 1100 ng/dL). Three levels of quality control samples were run in each analytical batch for androstenedione (20, 100, and 200 ng/dL), progesterone (40, 500, and 1200 ng/dL), corticosterone (10, 50, and 500 ng/dL), and testosterone (33, 275, and 550 ng/mL).
Samples for DHT analysis were thawed and samples were isotopically labeled. Internal standards were added to 200 mL aliquots of each sample following by extraction in a mixed solvent (3:2 ethyl acetate:hexane), and then washed with 0.1 M sodium hydroxide. The mixed solvent was evaporated to dryness and reconstituted with a 1 to 3 methanol/water mixture. Analysis was by HPLC and LC-MS/MS with electrospray ionization in the positive mode. One ion transition was monitored for each analyte and internal standard. Eight levels of calibration were run for DHT at 2, 5, 10, 20, 50, 150, 500, and 1000 ng/dL. Each calibration curve was calculated separately with QC samples for each analytical batch. The ratio of the peak area of the each analyte to the peak area of the internal standard versus concentration was calculated using a linear fit (x ¼ (y-b)/m; where y ¼ area ratio, x ¼ concentration, b ¼ intercept, and m ¼ slope) with 1/x weighting. These calculations were performed using the Applied Biosystems/MDS Sciex Analyst ® software version 1.4.1. All results for each analyte were reported to one significant figure for values less than 9, two significant figures for values up to 99, and to three significant figures for values exceeding 99. Numbers below the lower limit of quantification were reported as "< LLOQ".
Statistical analyses
Data are presented as mean ± standard error of the mean (SEM). Data were first tested for homogeneity of variances using the Bartlett's Chi Square Test (Bartlett, 1937) . Homogeneous data were evaluated by a parametric one-way analysis of variance [ANOVA] (Kruskal and Wallis, 1952) . Following ANOVA, a Bonferroni's Multiple Comparison Test was performed, comparing the vehicle group to the exposed groups, regardless of whether the ANOVA indicated a statistically significant difference (p 0.05). The positive controls (CPS and AA) were compared with the vehicle control group using the Student's t-test (Sokal and Rahlf, 1981) . In males, PF control group was compared to the vehicle control group and the 100 mg/ kg/day atrazine-treated group using the Student's t-test. Nonhomogeneous data were evaluated using a nonparametric analysis of variance (Wilson, 1956) . P values of 0.05 or less, as compared with the vehicle control group, were considered statistically significant.
Results
Findings in males 3.1.1. Body weights (BW) and food consumption
There was no difference in BW between treatment groups after a single day of treatment. In the 7-day treatment group, the mean BW of the 100 mg/kg/day animals was significantly lower than that of control animals on days 3 and 6 of treatment (F (3,252) ¼ 17.9; p < 0.0001; Supplemental Fig. 1, Supplemental Table 3 ). Body weight gain was reduced by approximately 60% relative to the control group over the 28 day treatment period, indicating that the maximum tolerated dose was exceeded in the highest-dosed atrazine group. The mean body weight gain for the PF rats was not statistically different from that for the 100 mg/kg/day treatment group. Animals treated with 100 mg/kg/day had reduced BW by day 6 of treatment, and this reduction was maintained throughout the treatment period. Pair-feeding of males resulted in a significant reduction in BW by day 3, which continued to be significant throughout 28 days (Supplemental Fig. 1 , Supplemental Table 3 ). In general, food consumption data mirrored the BW data, with the 100 mg/kg/day atrazine-treated group displaying significant reductions in food consumption throughout. There was no consistent effect on food intake in the 6.25 or 25 mg/kg/day atrazine-treated groups (data not shown). Males in the CPS positive control group displayed significant BW loss (10.4%) and reduced food intake over the 4 days of dosing with 50 mg/kg CPS. The NKC positive control group, which was administered a single dose of Anti-Asialo GM1, had an average BW loss of 7 g, although the reduction was not statistically significant (Supplemental Fig. 1 , Supplemental Table 3 ).
Plasma hormones and urinary corticosterone levels
Atrazine had no effect on ACTH levels in male rats on study days 1, 7, 14, or 28 (Fig. 1A) . Mean ACTH levels in the PF group were significantly greater than the mean control group levels on study day 28 (F (4,49) ¼ 3.8, p ¼ 0.009). Corticosterone levels were significantly elevated above control animals in all atrazine-treated animals after a single dose ( Fig. 1B; F (3,39) ¼ 10.3, p < 0.0001). There was no effect of atrazine treatment on corticosterone levels on days 7, 14, or 28. On day 28, the PF control group had significantly elevated corticosterone levels compared to the untreated controls and the 100 mg/kg group, to which its food availability was tethered (F (4,49) ¼ 5.5, p ¼ 0.0011). Similar to corticosterone, mean plasma progesterone was significantly elevated on day 1 in males administered 25 or 100 mg/kg atrazine ( Fig. 1C; F (3,39) ¼ 5.2, p ¼ 0.0045), but not at 6.5 mg/kg and not at any doses given after 7, 14, or 28 days. Mean plasma progesterone was not significantly greater than the control group mean in the PF group on day 28, but PF levels were elevated above 100 mg/kg treated animals (F (4,48) ¼ 6.4, p ¼ 0.0004).
On day 1 of treatment, the mean aldosterone level in the 100 mg/kg/day atrazine-treated group was significantly greater than the control group mean (Fig. 1D, F (3,39) ¼ 2.8, p < 0.05). No other atrazine treatment group was statistically different from vehicle control animals on day 1 and no treatment group was different from control animals after 7 and 14 days of treatment. On day 28, aldosterone levels were significantly less than controls in the PF group and in all atrazine-treated groups except the 6.5 mg/ kg groups (F (4,49) ¼ 5.2, p ¼ 0.0016). There was no difference in aldosterone levels between the PF and the 100 mg/kg atrazinetreated groups.
There was no effect of atrazine on group mean urinary corticosterone levels after 10 or 24 days of treatment ( Fig. 2; F (3,39) ¼ 2.0; p ¼ 131, F (3,39) ¼ 0.49; p ¼ 0.69; respectively). Urinary corticosterone levels observed in the PF control group were significantly greater than the vehicle control and 100 mg/kg atrazine-treated groups (F (4,49) ¼ 27.6; p < 0.0001) after 24 days of treatment. Serum prolactin levels, a hormone known to be somewhat responsive to stress, were highly variable. There was no significant effect of atrazine treatment on prolactin levels on day 1, 7, 14, or 28 (Supplemental Fig. 2) .
Overall, the gonadal hormones, testosterone, DHT, and androstenedione were not significantly affected by atrazine treatment ( Fig. 3AeC; F (9,137) ¼ 0.78, p ¼ 0.64, F (9,139) ¼ 1.3, p ¼ 0.26, F (9,141) ¼ 1.0, p ¼ 0.42, respectively), although a significant reduction in DHT was observed in the 25 mg/kg/day atrazine-treated group on day 28. PF animals had significantly lower mean testosterone, DHT, and androstenedione levels compared to vehicle control animals on day 28 ( Fig. 3AeC; F (4,48) ¼ 8.6, p < 0.0001, F (4,48) ¼ 6.5, p < 0.001, and F (4,47) ¼ 4.4, p < 0.005, respectively).
Plasma levels for estrone, estriol, and estradiol were at or below the LLOQ in all groups of males (data not shown). The LOQ was 2 pg/ mL for estradiol and estrone, and 10 pg/mL for estriol. Out of approximately 170 samples, no samples had detectable levels of estrone, 2 samples had detectable levels for estradiol, and 7 samples had detectable estrone levels using MS-HPLC. No statistical analyses were performed on the limited numbers of these samples above detection limits, although relative coefficients of variation (CVs) were calculated for androstenedione (4.65%), testosterone (3.33%), estrone (1.42%), estradiol (6.65%), estriol (3.35%), and aldosterone (6.46%).
Spleen and thymus weights
Atrazine had no effect on absolute or relative spleen weights compared with controls (Table 3 , F (3,180) ¼ 1.4, p ¼ 0.24; F (3,180) ¼ 1.9, p ¼ 0.13). A significant reduction in absolute mean thymus weight was observed in the 100 mg/kg/day atrazinetreated group compared with controls after 7, 14, and 28 days of Fig. 1 . Histograms depicting stress hormone levels (mean ± SEM) in male rats gavaged with 0, 6.5, 25, or 100 mg/kg of atrazine or animals allocated food tethered to that consumed by animals treated with 100 mg/kg for 1, 7, 14, or 28 days. Asterisks denote significant difference to 0 mg/kg of the same duration of treatment, p < 0.05. Hash marks denote a significance difference between the 100 mg/kg group compared to the PFC group. Fig. 2 . Histograms depicting urine corticosterone levels (mean ± SEM) in male rats gavaged with 0, 6.5, 25, or 100 mg/kg of atrazine or animals allocated food tethered to that consumed by animals treated with 100 mg/kg for 10 or 24 days. Asterisks denote significant difference to 0 mg/kg of the same duration of treatment, p < 0.05. Hash marks denote a significance difference between the 100 mg/kg group compared to the PFC group. treatment; relative thymus weights were unaffected by treatment, except for a reduction in relative thymus weights in the 100 mg/kg group compared to vehicle control group after 14 days of treatment (Table 4, F (3,144) ¼ 15.14, p < 0.0001, F (3,144) ¼ 9.7, p < 0.0001; respectively). There were no effects of atrazine on mean absolute or relative thymus weights in either the 6.5 or 25 mg/kg/day groups (Table 4) . There was no effect of pair feeding on absolute or relative spleen or thymus weights.
T-cell mediated antibody formation
No treatment-related reductions in IgM AFC numbers were seen with any dose of atrazine in male rats, irrespective of whether results were calculated as total AFC per spleen, or as AFC per 10 6 spleen cells (Table 5 , Fig. 4AeC ). In contrast, rats treated with CPS Fig. 3 . Histograms depicting gonadal hormone levels (mean ± SEM) in male rats gavaged with 0, 6.5, 25, or 100 mg/kg of atrazine or animals allocated food tethered to that consumed by animals treated with 100 mg/kg for 1, 7, 14, or 28 days. Asterisks denote significant difference to 0 mg/kg of the same duration of treatment, p < 0.05. Hash marks denote a significance difference between the 100 mg/kg group compared to the PFC group. displayed marked reductions in spleen weight and cellularity, and in the number of IgM AFC (Table 5) . The mean spleen cell number was significantly increased in PF animals when compared to the 100 mg/kg treated group (Fig. 4A) . Similarly, specific activity and total spleen activity showed significant reductions in the positive control groups but displayed no effects of atrazine treatment (Table 5 ; Fig. 4BeC ; F (5,59) ¼ 8.88, p < 0.0001, F (5,59) ¼ 8.57, p < 0.0001, respectively).
3.1.5. Natural killer cell activity Natural killer cell (NKC) activity was measured in male rats over a range of effector:target (E:T) cell ratios (Table 6) . No cytotoxicity was observed using E:T ratios of 25:1 or less. No treatment-related reductions in NKC activity were recorded at any dose of atrazine. However, a significant increase in NKC activity compared with vehicle-treated controls was recorded for animals that had received 100 mg/kg/day atrazine, and this was manifest at E:T ratios of 200:1 and 100:1 (Table 6 , Fig. 5AeB ; F (5,59) ¼ 14.98, p < 0.0001, F (5,59) ¼ 12.4, p < 0.0001, respectively). At a ratio of 50:1, there was no significant effect of atrazine treatment on NKC activity (Fig. 5C , Table 6 ). Pair-feeding had no effect on NKC activity at any E:T ratio. Treatment with the positive control, AA, significantly decreased NKC function (Fig. 5, Table 6 ).
Findings in females 3.2.1. Achieved doses in dietary subgroups
Based on body weight and food consumption data, the 28-day average doses received by female rats administered 30 or 500 ppm atrazine in their diets were approximately 3 and 51 mg/ kg/day, respectively.
Body weights and food consumption
Body weight was significantly reduced in the 500 ppm atrazinetreated group compared to controls in each of the AFC and NKC treatment cohorts (Supplemental Fig. 3 , Supplemental Table 4 ; AFC:F (7,79) ¼ 2.3, p < 0.05, NKC: F (7,79) ¼ 4.1, p < 0.001). There was no effect of treatment on BW in the 30 ppm atrazine group. Slightly lower mean BW gains were noted intermittently throughout the 28-day treatment period in the AFC and NKC treatment cohorts administered atrazine by gavage at doses of 6 and 50 mg/kg/day. There were no effects of treatment on BW in the 3 mg/kg/day dose group. Food consumption was highly variable and not consistently reduced in any of the atrazine dietary or oral gavage groups (Supplemental Fig. 4) . The 4-day periodicity, noted in both food intake (Supplemental Fig. 4 ) and BW (Supplemental Fig. 3) , was attributed to the fact that the estrous cycle of the animals was synchronized at the commencement of dosing on study day 1.
Animals in the AFC cohort administered CPS by intraperitoneal injection at a dose of 50 mg/kg/day from study day 24e28 displayed significantly lower BW compared to control animals on study day 28 (Supplemental Table 4 ). The mean BW of females assigned to the NKC assay positive control group (single injection of Anti-Asialo GM1) was not statistically different from the vehicle control group.
Plasma hormones and urinary corticosterone levels
There were no significant differences in plasma corticosterone levels in atrazine-treated female rats in either the dietary or the bolus dose groups (Fig. 6A, F (2,29) ¼ 2.7, p ¼ 0.08; F (3,39) ¼ 0.5, p ¼ 0.66, respectively). Dietary atrazine did not affect progesterone levels (Fig. 6B, F (2,28) ¼ 1.7, p ¼ 0.21) . ANOVA analysis of progesterone levels in animals gavaged with atrazine was statistically significant (Fig. 6B, F (3,39) ¼ 3.1, p ¼ 0.04). However, post hoc analysis determined that differences were not between the vehicle control and any of the treatment groups (only between the 3 and 50 mg/kg atrazine groups). Aldosterone levels were reduced in dietary atrazine groups, but these reductions were not statistically significant (Fig. 6C , F (2,28) ¼ 1.1, p ¼ 0.33). Likewise, in the bolus treated atrazine group of 50 mg/kg, aldosterone levels were reduced compared to control animals, but the difference was not statistically significant (Fig. 6C, F (3, 39) 
Urinary corticosterone levels ( Fig. 7) were reduced in the 50 mg/ kg group compared to the control group at the 0e6 h (F (3,79) ¼ 2.15, p ¼ 0.10), 9e15 h (F (3,79) ¼ 4.0, p ¼ 0.011) and the 18e24 h (F (3,79) ¼ 0.28, p ¼ 0.84) intervals, but the difference was only statistically significantly at the 9e15 h interval. There were no effects of atrazine at lower doses.
Gonadal hormones results were similar between dietary vs. bolus atrazine treatment groups (Fig. 8) . Overall, there was no significant effect of atrazine on androstenedione (diet: F (2,28 
Spleen and thymus weights
Exposure of female rats to atrazine by gavage at doses of 3, 6, or 50 mg/kg/day had no effect on absolute or relative thymus or spleen weights (Table 7 ). In the NKC cohort, there were no effects of atrazine treatment on thymus weight in the dietary or oral gavage subgroups. Absolute wet spleen weight (diet: F (2,29) ¼ 1.65, p ¼ 0.21, bolus: F (3,39) ¼ 1.16, p ¼ 0.34) and spleen weight relative to final BW (diet: F (2,29) ¼ 0.28, p ¼ 0.76, bolus: F (3,39) ¼ 2.13, p ¼ 0.11) were also unaffected by atrazine treatment. In the AFC cohort, there was no effect of atrazine treatment on absolute ( In the NKC assay, the positive test article, AA, had no effects on either absolute or relative spleen weight when compared to control groups from either the bolus or dietary dose groups (F (2,29) ¼ 0.09, p ¼ 0.91 and F (2,29) ¼ 0.24, p ¼ 0.79, respectively). Similarly, there were no effects of AA on either absolute (F (2,29) ¼ 0.35, p ¼ 0.71) or relative (F (2,29) ¼ 0.12, p ¼ 0.89) spleen weight when compared to control groups. In the AFC assay cohort, there was an effect of the positive control CPS on absolute (F (2,29) ¼ 39.93, p < 0.0001) and relative (F (2,29) ¼ 48.47, p < 0.0001) spleen weight when compared to control groups.
T-cell mediated antibody formation
Twenty-eight days of atrazine administration by gavage or in diet had no effect on humoral immune function in female rats. There were no differences in the number of spleen cells ( Fig. 9A ; diet:F (3,39) ¼ 21.7, p < 0.0001, bolus: F (4,49) ¼ 18.3, p < 0.0001) or the Fig. 4 . Histograms depicting the mean ± SEM of spleen cell number (A), specific activity (B), and total spleen activity (C) in male rats gavaged with 0, 6.5, 25, or 100 mg/kg of atrazine or animals allocated food tethered to that consumed by animals treated with 100 mg/kg for 28 days. Positive control animals were given the immunotoxic 50 mg/kg CPS. Asterisks denote significant difference to 0 mg/kg of the same duration of treatment, p < 0.05. Hash marks denote a significance difference between the 100 mg/kg group compared to the PFC group. 0 mg/kg 7.9 ± 1.2 3.3 ± 0.7 1 1 1 1 828.5 ± 35.8 6.5 mg/kg 8.3 ± 1.0 3.7 ± 0.6 1 1 1 1 828.4 ± 36.6 25 mg/kg 7.9 ± 1.3 2.7 ± 0.6 1 1 1 1 850.8 ± 34.7 100 mg/kg 11.9 ± 0.9 , 50:1 (C) cell ratio in male rats gavaged with 0, 6.5, 25, or 100 mg/kg of atrazine or animals allocated food tethered to that consumed by animals treated with 100 mg/kg for 28 days. Positive control animals were given the immunotoxic AA at 1:10 dilution. Asterisks denote significant difference to 0 mg/kg of the same duration of treatment, p < 0.05. Hash marks denote a significance difference between the 100 mg/kg group compared to the PF group.
number of IgM AFC that responded to immunization with SRBC (Table 8 , Fig. 9BeC ; diet:F (3,39) ¼ 10.0, p < 0.0001, bolus: F (4,49) ¼ 8.7, p < 0.0001; diet:F (3,39) ¼ 12.3, p < 0.0001, bolus: F (4,49) ¼ 9.4, p < 0.0001). Atrazine, administered either by gavage or in the diet at any dose, had no effect on either the total number of IgM AFC per spleen or the number of AFC per 10 6 spleen cells, compared with vehicle treated controls. Treatment of female rats with CPS as a positive control caused a substantial reduction in absolute and relative spleen weights, a profound reduction in the number of spleen cells, and a reduction in the number of IgM AFCs.
3.2.6. Natural killer cell activity Atrazine did not have any effect on NKC function (Table 9 , Fig. 10 ) in female SD rats administered atrazine by gavage or in the diet for 28 days. The activity of splenic NKC was evaluated at a variety of E:T ratios. In no instance did atrazine exposure at any dose, administered either by gavage or in the diet, have any influence on NKC-mediated cytotoxicity. Rats that had received the AAGM1 antibody displayed significantly lower levels of NKC activity at E:T ratios of 200:1 (diet: F (3,39) ¼ 3.6, p ¼ 0.02; bolus: F (3,39) ¼ 3.1, p ¼ 0.02), but not at lower dilutions (Table 9 , Fig. 10BeC ).
Discussion
In this study there was no evidence of any decrement of immune function (IgM antibody production, or NKC activity) in SD rats administered atrazine for 28 days by gavage (males and females) or in the diet (females) at maximally-tolerated doses. The only effect of atrazine on lymphoid tissue was a significant reduction in absolute thymus weight in male rats in the 100 mg/kg/day atrazinetreated group on day 7, 14, and 28. These doses also resulted in a significant decrease in body weight gain over the 7e28 day treatment periods. The relative thymus weight was decreased only in the 14-day treatment group. These results are consistent with the findings in immunotoxicity parameters assessed in regulatory studies conducted on atrazine (Supplemental Table 5 ).
Published studies investigating the effect of single doses of atrazine on the immune system in the mouse (Pruett et al., 2003) yielded results that conflict with the present study in rats administered atrazine daily by gavage for 28 days. Single doses of atrazine (100, 200, or 300 mg/kg) administered to female C57BL/6 mice by intraperitoneal injection or 500 mg/kg by oral gavage reduced thymus and spleen cellularity and reduced splenic NKC activity at several effector to target cell ratios (Pruett et al., 2003) . Atrazine increased the number of CD4 þ and CD8 þ cells in a dose-dependent manner and decreased the antibody response (IgG1 and IgG2a) to the keyhole limpet hemocyanin antigen (Pruett et al., 2003) . In a study conducted by the National Toxicology Program (Karrow et al., 2005; Program, 1994) , the immunotoxicity of atrazine was assessed in mice administered atrazine by oral gavage (0, 24, 250, and 500 mg/kg/day) for 14 days. Thymus weights, spleen weights, total spleen cell numbers, and fixed macrophage function were reduced in all atrazine-treated groups (Karrow et al., 2005) . The mean number of splenic CD8 þ T cells, cytotoxic T cell, and mixed leukocyte responses were statistically significantly increased in the 500 mg/kg/day atrazine-treated group. Atrazine had no effect on the IgM antibody response to SRBC, and NKC activity was unchanged, although a reduction in host resistance to challenge with B16F10 was reported. Pruett observed a linear dose-response relationship between area under the curve (AUC) corticosterone concentration and a number of immunological responses to stress, irrespective of whether stress was induced by physical restraint or caused directly by corticosterone injection (Pruett, 2001; Pruett et al., 1999 Pruett et al., , 2000 Pruett and Fan, 2001) . They also showed that the plasma AUC for atrazine was predictive of the same suite of immunological responses as were predicted by corticosterone and restraint stress, suggesting that the effects of a single dose of atrazine might be Fig. 6 . Histograms depicting stress hormone levels (mean ± SEM) in female rats given diets with 0, 30, or 500 ppm of atrazine or gavaged with 0, 3, 6, or 50 mg/kg of atrazine for 28 days. Asterisks denote significant difference to 0 mg/kg of the same duration of treatment, p < 0.05. Fig. 7 . Histograms depicting urine corticosterone levels (mean ± SEM) in female rats given diets with 0, 30, or 500 ppm of atrazine or gavaged with 0, 3, 6, or 50 mg/kg of atrazine for 28 days. Asterisks denote significant difference to 0 mg/kg of the same duration of treatment, p < 0.05. mediated by a dose-dependent activation of the HPA axis. Pruett et al. (2003) also reported a substantial reduction of MHC class II cells after a single injection of atrazine in mice. Few stimuli other than stressors have been shown to downregulate MHC class II (primarily splenic B cells) expression (Celada et al., 1993; Zwilling et al., 1990 Zwilling et al., , 1993 . To our knowledge, no drugs or chemicals have been reported to suppress basal MHC class II expression, except by inducing a stress response. In support of this hypothesis, Pruett et al. (1999) reported that exogenous corticosterone and restraint stress were both sufficient to suppress NKC activity in a similar fashion to that observed following a single atrazine dose.
A key result from the present study was that the atrazineinduced activation of the HPA axis, observed after a single dose, habituated after successive doses such that plasma concentrations of corticosterone and progesterone levels were not different from control animals after 7, 14, and 28 days of treatment. ACTH levels were not found to be statistically significantly elevated above control levels on any day of treatment, despite a trend upward with higher atrazine doses on day 1 of treatment. This is in contrast to previous reports of atrazine-induced ACTH (Fraites et al., 2009; Hotchkiss et al., 2012; Laws et al., 2009) . The increased variance in the hormone levels cannot be fully explained. However, atrazineinduced ACTH plasma concentrations have been shown to peak at 15 min post gavage in rats and then drop precipitously at later time points (Laws et al., 2009) . In the present study, blood samples were collected 30 min post gavage, when atrazine-induced corticosterone levels are known to be peaking (Laws et al., 2009 ). Aldosterone, another adrenal hormone which can be stimulated by ACTH, was elevated above vehicle-treated animals after a single dose (Fig. 1 ), but not after 7 and 14 days of treatment, suggesting habituation or tolerance. Unlike the other stress hormones, aldosterone levels were significantly lower than those of vehicletreated control animals in all atrazine doses and PF animals at 28 days. The most likely explanation for this finding is the unexplained rise in aldosterone levels in the control group.
Few studies have examined the effect of atrazine on stress hormones after multiple doses. Of the studies that measured stress hormones after 4 daily treatments, both ACTH (Fraites et al., 2009) and progesterone (Goldman et al., 2013 ) levels of animals treated with 75e100 mg/kg of atrazine were not elevated above vehicletreated control animals. Plasma ACTH and progesterone levels were significantly reduced after 4 days of treatment when compared to a single dose of atrazine. Riffle et al. (2013) reported an elevation in progesterone after 5 days of atrazine at 200 mg/kg, with no significant change in corticosterone from control levels (Riffle et al., 2013) . In contrast to the present results in rats, Pruett et al. (2009) found that the corticosterone response observed in female C57BL/6 mice after a single atrazine dose of 200 mg/kg administered by intraperitoneal injection was comparable to the response observed after 28 daily atrazine doses of 150 mg/kg/day (Pruett et al., 2003) .
Irrespective of whether the mouse or the rat is a better model to investigate the immunotoxic potential of atrazine in humans, it is likely that the immune response to atrazine depends on the Fig. 8 . Histograms depicting gonadal hormone levels (mean ± SEM) in female rats given diets with 0, 30, or 500 ppm of atrazine or gavaged with 0, 3, 6, or 50 mg/kg of atrazine for 28 days. Asterisks denote significant difference to 0 mg/kg of the same duration of treatment, p < 0.05. administration of bolus doses to activate the HPA axis. After a single dose of atrazine, administered by gavage to either male or female rats, there was a rapid rise in plasma ACTH followed by an elevation in the plasma concentration of the adrenal hormones progesterone and corticosterone (Fraites et al., 2009; Laws et al., 2009 ). This response subsided within 3e12 h, depending on the dose level (Foradori et al., 2011; Laws et al., 2009 ). These studies also demonstrated that atrazine was slightly less potent than DEA and DIA in triggering the HPA stress response, whereas DACT was ineffective. Interestingly, following gavage dosing, atrazine, DEA, and DIA have relatively short half-lives in plasma, whereas the halflife of DACT was more prolonged (see Supplemental Fig. 5 ) (Campbell et al., 2016) . Administration of atrazine in the diet over 4 successive 24 h periods did not lead to peak plasma concentrations of atrazine, DEA, or DIA that compare to those observed after bolus dose administration. DACT plasma concentrations in the dietary subgroups were similar to, but less spiky than, those found after bolus dose administration (Supplemental Fig. 5 ).
Chemical-induced tolerance or habituation within the HPA axis has been reported previously (Valles et al., 2002) . Indeed, if the immunosuppressive properties of atrazine are linked to HPA activation, the present results suggest that animals no longer respond to atrazine treatment with HPA activation between 2 and 7 days of treatment in males. Likewise, males show no increase in stress hormones after 14 days, and neither gender has elevated adrenal steroids after 28 days of treatment. This holds true for urine corticosterone levels as well, with no increase in urine corticosterone levels after 10 or 24 days of atrazine treatment in males or after 22 days of treatment in females. The lack of a rise in urine corticosterone correlates with the lack of immunological changes in rats (Pruett et al., 2008) . Although previous studies suggested that atrazine treatment may result in an increased concentration of androgens or estrogens in vivo (Hahn et al., 2016; Higley et al., 2010; Holloway et al., 2008; Laville et al., 2006; Quignot et al., 2012a; Sanderson et al., 2000; Stoker et al., 2000 Stoker et al., , 2002 Tinfo et al., 2011) , we found no evidence of such effects in male or female rats administered atrazine for up to 28 days; the exception was that males treated with 25 mg/kg for 28 days had a lower DHT levels when compared to controls. One notable difference between the present investigation and published studies is that other investigators relied upon radioimmunoassays or ELISAs for the quantification of androgens and estrogens, whereas we used LC-MS/MS and a stable 13 C label to identify and quantitate gonadal hormones. It is known that RIA methods can lack specificity due to cross-reactivity, which may become important at low hormonal levels (Rosner et al., 2007 (Rosner et al., , 2013 . In the present study, atrazine treatment had no effect on estrogen levels in females and in males, and plasma concentrations of estrogens were at levels at or below the limit of detection. Androgen levels were unchanged due to atrazine treatment. In the few published studies that used LC-MS/ MS, there was no evidence of changes in plasma estrogen or androgen concentrations after atrazine treatment (Quignot et al., 2012b; Tournier et al., 2015) . Quignot et al. (2012b) extracted samples directly from ovaries of atrazine-treated rats (200 mg/kg for 14 days) and found no change in androstenedione, testosterone, or estradiol, with a small rise in estrone (Quignot et al., 2012b) . Tournier et al. (2015) reported no effect of atrazine on absolute sex hormone levels, but found an elevation of estradiol/testosterone ratio in females. The authors postulated that the ratio change was suggestive of increased aromatase activity, but there was no change in the estrone/androstenedione ratio (Tournier et al., 2015) . Similar to the current findings, Goldman et al. (2013) , did not find any effect of atrazine on estradiol levels in intact females (Goldman et al., 2013) , however, Riffle et al. (2013) reported increased estrone and estradiol levels after 5 days of atrazine treatment (200 mg/kg) in Table 7 Mean absolute and relative spleen and thymus weights (i.e., relative to body weight)dfemales. Treatment The current results suggest that after repeated exposure to atrazine animals become habituated or desensitized to the HPAactivating properties of atrazine. Currently, little is known regarding the mechanism by which atrazine acts to activate the HPA. Therefore, it is not known how this habituation may occur. We have observed that the expression of a number of CYP liver enzymes involved with the oxidative metabolism of atrazine and GST enzymes involved with the conjugation of atrazine and its chlorometabolites increase after repeated doses (unpublished data). Thus, the rate of metabolism and clearance of atrazine may be altered sufficiently so that plasma atrazine and metabolite levels do not reach threshold levels required for HPA activation after repeated dosing. Indeed, the primary atrazine metabolite in the rat, DACT, does not activate the HPA to the same degree as its atrazine precursor (Hotchkiss et al., 2012) . It is also not known if the atrazine habituation would persist after cessation of atrazine treatment, or if cross-habituation would occur to homotypic stressors, or if there were would be sensitization to novel stressors (Herman, 2013) . Lower urine corticosterone concentrations during the 9 h-15 h collection period in female rats treated with 50 mg/kg of atrazine may also suggest a blunting, or perhaps a shift, in the diurnal corticosterone rhythm. More work is need to determine how atrazine stimulates the HPA and if there are long-term effects to repeated exposures to the HPA.
Collectively, the results from this study indicate that exposure of male rats for 28 days to atrazine by gavage at doses of up to 100 mg/ kg/day is without impact on immunological function. Similarly, Fig. 9 . Histograms depicting the mean ± SEM of spleen cell number (A), specific activity (B), and total spleen activity (C) in female rats given diets with 0, 30, or 500 ppm of atrazine or gavaged with 0, 3, 6, or 50 mg/kg of atrazine for 28 days. Positive control animals were given the immunotoxic 50 mg/kg CPS. Asterisks denote significant difference to 0 mg/kg of the same duration of treatment, p < 0.05. there were no effects on any immune parameters examined following exposure of female rats to atrazine at oral (gavage) doses of up to 50 mg/kg/day, or at dietary concentrations up to 500 ppm. These results are consistent with the observation that activation of the HPA axis by atrazine is short-lived, with no increase in adrenal hormone levels in atrazine-treated animals compared to controls by day 7. Furthermore, because of the rapid dealkylation of atrazine to DEA, DIA, and eventually to DACT (Campbell et al., 2016) , which does not activate the HPA axis (Fraites et al., 2009) , it is unlikely that temporally-distributed doses, such as those used in the feeding study in females, would activate the HPA axis. Finally, because humans are potentially exposed to low levels of chlorotriazine in small doses that are temporally-distributed over the day, it is unlikely that atrazine or its chlorotriazine metabolites would trigger an adrenal stress response or immunotoxic sequelae in humans (Breckenridge et al., 2016) .
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